Answer to UBS’s chronic US problem may be M&A
Sergio Ermotti has a U.S. problem. The UBS boss acknowledged as much on Tuesday by releasing some new targets for the ...
Is Geron A Buyout Target? The RPRX Deal Says No
We argue against selling Geron at current prices, citing strong market potential of imetelstat and Royalty Pharma deal ...